Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
TAB trial: tirzepatide plus buprenorphine
The recruiting TAB trial will test tirzepatide added to buprenorphine for opioid use disorder, but its design paper reports no outcomes.
Tirzepatide in a UK digital cohort
A 630,545-person UK tirzepatide cohort reported substantial weight loss, but missing weights and self-pay selection limit interpretation.
ADCY4 Atherosclerosis Mouse Study
A laboratory study links endothelial ADCY4 to vascular inflammation and semaglutide effects in cells and mice, not to a new human treatment result.
GLP-1 Drugs and AF in Obesity With CKD
A matched cohort linked GLP-1 receptor agonist use with less one-year atrial fibrillation in non-diabetic adults with obesity and CKD.
GLP-1 Therapies in ESRD: 2026 Meta-Analysis
A 2026 meta-analysis pooled 19 studies and 388 patients with end-stage renal disease, but most treatment-specific estimates concerned semaglutide.
Japan's GLP-1 treatment cap and regain
A prospective Japanese cohort tracked weight before, during and after time-limited semaglutide or tirzepatide treatment.
GLP-1 Weight-Loss Drugs: Trial Review
A 24-trial network meta-analysis ranked obesity medicines, but high heterogeneity and indirect comparisons limit claims of superiority.
Nerve risks after weight loss drugs
A 2026 review links rare peripheral nerve problems with rapid weight loss during semaglutide or tirzepatide treatment.
MASH Trials: Resmetirom and Semaglutide
Two phase 3 trials support resmetirom and semaglutide in MASH, but their separate designs do not establish which treatment works better.
Semaglutide and Smoking in HIV
A cohort study linked semaglutide initiation to lower cigarette use among people with HIV, but it cannot show that the medicine caused the change.
Tirzepatide Injection Route Error
A single tirzepatide case report links accidental intradermal injection with increased adverse events, but cannot measure the risk.
Tirzepatide and TLR2 Inflammation in Mice
A mouse and cell study found tirzepatide reduced selected inflammatory responses after a Western diet. It was not a clinical outcomes trial.